Please click here for important safety information including boxed WARNING of Micardis and Micardis HCT
BLood Pressure Protection

Educational Materials


BPprotection.com offers useful, relevant, and valuable medical education content about hypertension to healthcare professionals through the links below. In addition to enjoying the informative literature reviews and podcasts featuring thought leaders in the field of hypertension, please take a few moments to browse the calendar of events and make note of any educational activity that may be of interest to you or your colleagues and peers.

As the information on the site is continually being updated and new content added periodically, we invite you to visit frequently or to create a bookmark to this page by clicking here.


Article Commentary Calendar of Events
Quote of the Month Podcasts
Getting to Know Micardis 3 vs. 600




USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, MICARDIS® (telmisartan) and MICARDIS® HCT (telmisartan/hydrochlorothiazide) should be discontinued as soon as possible (see WARNINGS: Fetal/Neonatal Morbidity and Mortality)


MICARDIS and MICARDIS HCT are indicated for the treatment of hypertension.
MICARDIS HCT is not indicated for initial therapy.
Please see full Prescribing Information, including boxed WARNING, using the link below.
Home   |   Prescribing Information   |   Terms of Use   |   Privacy   |   Contact Information